Concentrations of trovafloxacin were measured in serum, alveolar macrophages, epithelial lining fluid and bronchial mucosa following single and multiple oral doses. Concentrations were determined using a microbiological assay method. There were 18 subjects in the single dose and nine subjects in the multiple dose groups. After single dosing, mean concentrations in serum, alveolar macrophages, epithelial lining fluid and bronchial mucosa at 6, 12 and 24 h were as follows: 6 h, 
Introduction
Trovafloxacin (CP-99,219) is a new azabicyclic naphthyridone structurally related to the fluoroquinolones. 1 It has a broad spectrum of activity, with the advantage of being more active against Gram-positive cocci, including Streptococcus pneumoniae, than other marketed fluoroquinolones. 2 The aim of this study was to assess the concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid (ELF) and alveolar macrophages in comparison with those of serum up to 24 h after a single oral dose before bronchoscopy. In order to reflect the concentrations likely to be found in clinical practice, concentrations were also measured in patients, 6 h after the last of four successive daily doses.
Patients and methods
Totals of 18 (15 males, three females) and nine (seven males, two females) patients undergoing elective fibreoptic bronchoscopy in single and oral dose groups respectively were studied. All subjects were over 18 years of age and all female subjects were post-menopausal. The study was approved by the Hospital Ethics Committee and all patients gave written informed consent.
Patients with active lung infection, on antibiotic therapy or with severely compromised respiratory status were excluded from the study as were those with significant renal disease (serum creatinine 170 mg/L) or hepatic disease (SGOT greater than twice the upper limit of the laboratory normal). Patients with a history of allergy to quinolones, multiple drug sensitivity or photosensitivity were also excluded. Subjects were excluded if they were taking antacids, anticoagulants, iron salts or agents with CNS activity.
Dosage regimen
This was an open study designed to assess the distribution of trovafloxacin in bronchial tissues and fluids following the administration of a single 200 mg oral dose or multiple 200 mg oral dosing for four successive days.
Single dose regimen. Eighteen patients were studied. After a fast of at least 3 h a single dose of 2 100 mg trovafloxacin
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Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy was administered with 150 mL of water. Patients were allocated to three bronchoscopy groups each with six subjects as follows: group 1, 6 h post-dose; group 2, 12 h post-dose; group 3, 24 h post-dose.
Multidose regimen. Nine patients received the multidose regimen. Each patient received a single administration of 2 100 mg of trovafloxacin per day on four successive days. Bronchoscopy was performed 6 h after the last dose.
Sample collection and processing
A standard bronchoalveolar lavage (BAL), using 200 mL of pre-warmed 0.9% saline (lavage divided into four 50 mL aliquots) was performed followed by gentle aspiration. To avoid contamination with proximal airway cells and fluids the first 50 mL was discarded. 3 The aspirate from the last three aliquots was pooled and then divided into two Teflon containers (used to avoid the loss of macrophages by sticking to surfaces) so that concentrations in ELF and macrophages could be determined in duplicate. A small amount of lavage from each of the samples was removed, using silanized glassware, into an improved Neubauer counting chamber so that the number of macrophages in the lavage could be counted under a microscope. The remainder of the lavage was centrifuged immediately (in the endoscopy suite) at 400g for 5 min. After centrifugation the supernatant was separated from the cells without delay. Approximately 2 mL of the supernatant was removed so that the urea level in the lavage sample could be measured; the remainder of the supernatant was used to measure the concentration of trovafloxacin present. The lavage sample was freeze-dried and then reconstituted with distilled water to one-tenth the original volume. Macrophages were ultrasonicated on ice in a known volume of chilled pH 7 phosphate buffer before assay (100% duty cycles MISONIX Model XL2015, Life Science Laboratories, Luton, UK). Bronchial biopsies were collected into a humidity chamber to avoid loss of moisture from the tissue, 4 any blood-stained tissue being discarded. Tissue was weighed and then ultrasonicated in a known volume of pH 7 buffer. Serum samples were taken at the end of the bronchoscopy. All samples were stored at 4°C and protected from light before assay. With the exception of the lavage supernatant, all assays were performed within 1 h of collection.
Microbiological assay
Concentrations of trovafloxacin were measured using an adaptation of a microbiological assay previously described. 5 Briefly, levels were determined using IsoSensitest agar (CM 471, Unipath, Basingstoke, UK) as assay media and Escherichia coli 4004 (Bayer AG, Wuppertal, Germany) as assay organism. Calibrators, internal controls (fixed concentrations prepared from a different weighing of standard material) and quality assurance samples (prepared independently by an individual not performing the assays, at variable concentrations similar to those expected from the subject samples) were prepared in human serum (Bradsure Biologicals, UK) for human serum samples, in pH 7 phosphate buffer for biopsy and macrophage samples and in 9% sodium chloride for concentrated BAL samples. The calibrator concentrations for human serum were 2, 1, 0.5, 0.25 and 0.125 mg/L with internal control concentrations of 1.5 and 0.2 mg/L. The calibrator concentrations for pH 7 phosphate buffer and 9% sodium chloride were 1, 0.5, 0.25, 0.125 and 0.06 mg/L with internal controls of 0.8 and 0.08 mg/L. Quality assurance samples were made over a range of 0.2-1.8 mg/L for human serum (a total of 39 samples tested) and 0.08-1.06 mg/L for pH 7 phosphate buffer and 9% sodium chloride (a total of 26 9% sodium chloride and 36 pH 7 phosphate buffer samples prepared).
Plates were incubated in air for 18-24 h at 30°C. After incubation, zones were measured using an image analyser (Vidas 2.5, Kontron Instruments, Thame, UK) and a line of best fit constructed using Bennet's calculation. 6 The lower limit of detection for human serum was 0.03 mg/L and for pH 7 phosphate buffer and 9% sodium chloride was 0.015 mg/L. All measurable concentrations were within the standard curve. 
Methods of analysis

Calculation of antibiotic concentration in macrophages.
Using data derived by Johnson et al. 8 antibiotic concentration was determined using a mean cell volume of an alveolar macrophage of 2.48 L/10 6 cells.
Results
The coefficient of variation of the method to measure urea in BAL was 7.8% (data not shown). Coefficients of variation for the human serum (1.5 and 0.2 mg/L), pH 7 phosphate buffer (0.8 and 0.08 mg/L) and the 9% sodium chloride (0.8 and 0.08 mg/L) internal controls were 7.65 and 6.57, 6.9 and 9.81 and 6.13% and 6.55%, respectively. These results confirm the precision of the assay method, all coefficients of variation being 10%. Mean percentage errors for the quality assurance samples for human serum, pH 7 phosphate buffer and 9% sodium chloride were 5.02, 11.12 and 7.35%, respectively.
The mean biopsy weight, lavage volume, lavage urea and macrophage count for the 27 patients were 11.25 mg (S.D. Statistical analysis of the paired data for ELF and macrophage concentrations showed no statistically significant difference (P 0.3711 and 0.6979, respectively). Figures 1 and 2 show the concentrations of trovafloxacin in serum, bronchial mucosa, ELF and alveolar macrophages following single and multiple dosing plotted against time after the last dose related to the MIC 90 s for the common respiratory pathogens, Moraxella catarrhalis and Streptococcus pneumoniae are also shown. 2 The corresponding data, including site:serum ratio, are also tabulated in Tables I and II serum were similar to those found for the single dose (means 1.41 and 1.47 mg/L, respectively). Site:serum ratios were also similar for mucosa (mean 1.07 and 1.12, respectively); however, ratios were higher in ELF (mean 2.27 and 5.85, respectively) and alveolar macrophages (mean 13.32 and 24.10, respectively).
No adverse events occurred during or immediately after the study. There was no significant alteration in any haematological or biochemical parameter.
Discussion
This study has shown clinically significant concentrations of trovafloxacin at all potential sites of respiratory infection for up to 12 h post-dose. There were no measurable concentrations in mucosa 24 h after a single dose. Assuming a mucosa:serum ratio of 1 and using the equation to calculate the amount of tissue needed to measure trovafloxacin, all of the subjects had biopsy weights below the theoretical minimum. The differences in site:serum ratios observed is unlikely to be attributed to errors in measurement of drug concentration (paired t-tests for ELF and macrophage concentration; P 0.371 and 0.6979, respectively). It is more likely to be a reflection of individual patient variation. Comparing site:serum ratios for the multiple dose regime with other quinolones, trovafloxacin ratios for bronchial mucosa are similar to those reported for ciprofloxacin (1.7 at 0-6 h). 10 For ELF and macrophages, ratios are higher than those reported for multiple dose ciprofloxacin, 11 
and temafloxacin 12 (ELF, 1.9, 2.8 and 3.1; macrophages, 14.3, 15.8 and 9.3, respectively). The levels of other quinolones in the ELF have also been found to be higher than simultaneous serum and bronchial biopsy levels.
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The mean serum and tissue levels of trovafloxacin exceeded the MIC 9 0 for the common respiratory pathogens, except in bronchial mucosa at 24 h following a single oral dose. This is particularly important with regard to S. pneumoniae, where earlier quinolones such as ciprofloxacin have only borderline activity. Trovafloxacin may therefore have a role in the treatment of lower respiratory tract infections caused by the common respiratory pathogens (ELF concentrations exceed MIC 90 s) and also macrophage levels may indicate a high level of efficacy against atypical pathogens. Abbreviations as in Table I .
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